|
Hypertensive disease
|
0.550 |
Therapeutic
|
group |
RGD |
Antihypertensive effects of peroxisome proliferator-activated receptor-β activation in spontaneously hypertensive rats.
|
21825230 |
2011 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
PSYGENET |
RGS2 and RGS5 genotypes predicted severity of baseline symptoms in schizophrenia.
|
18262772 |
2008 |
|
Schizophrenia
|
0.310 |
GeneticVariation
|
disease |
LHGDN |
RGS2 and RGS5 genotypes predicted severity of baseline symptoms in schizophrenia.
|
18262772 |
2008 |
|
Atherosclerosis
|
0.020 |
Biomarker
|
disease |
LHGDN |
Expression profiling identifies smooth muscle cell diversity within human intima and plaque fibrous cap: loss of RGS5 distinguishes the cap.
|
16293795 |
2006 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Whole-Genome Sequencing Coupled to Imputation Discovers Genetic Signals for Anthropometric Traits.
|
28552196 |
2017 |
|
Periprosthetic osteolysis
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The 2018 Otto Aufranc Award: How Does Genome-wide Variation Affect Osteolysis Risk After THA?
|
30794219 |
2019 |
|
Hypertensive disease
|
0.550 |
Therapeutic
|
group |
CTD_human |
[A muscle mutant of Drosophila melanogaster: the electron microscopic study of the indirect flight musculature].
|
1798635 |
1992 |
|
Essential Hypertension
|
0.320 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
Hypertensive disease
|
0.550 |
Biomarker
|
group |
BEFREE |
This is consistent with dysregulated (RGS5-mediated) AT<sub>1</sub>R signaling that could contribute to excessive vasoconstriction in hypertension.
|
29061726 |
2017 |
|
Hypertensive disease
|
0.550 |
Biomarker
|
group |
BEFREE |
Multiple SNPs in combination in RGS5 may confer risk for hypertension.
|
19863299 |
2009 |
|
Hypertensive disease
|
0.550 |
AlteredExpression
|
group |
BEFREE |
Here, we investigated the influence of regulator of G protein signaling 5 (RGS5), an inhibitor of Gα<sub>q/11</sub> and Gα<sub>i/o</sub> activity, on blood pressure and the VSMC phenotype during experimental hypertension.
|
29208700 |
2018 |
|
Hypertensive disease
|
0.550 |
GeneticVariation
|
group |
BEFREE |
In this study, we investigated the association between RGS5 gene variants and hypertension in the Mongolian and Han populations.
|
26782409 |
2015 |
|
Hypertensive disease
|
0.550 |
GeneticVariation
|
group |
BEFREE |
The strongest signal for hypertension was for rs2815272 in the RGS5 gene (P = 9.3 × 10).
|
21881522 |
2011 |
|
Essential Hypertension
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Thus, we assessed the relationship between RGS5 genetic polymorphisms and essential hypertension (EH) in Chinese.
|
19863299 |
2009 |
|
Essential Hypertension
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Association of regulator of G protein signaling (RGS5) gene variants and essential hypertension in Mongolian and Han populations.
|
26782409 |
2015 |
|
Schizophrenia
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
RGS2 and RGS5 genotypes predicted severity of baseline symptoms in schizophrenia.
|
18262772 |
2008 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Similarly, RGS-5 is overexpressed in highly angiogenic astrocytomas but not in hypoxia-inducible factor-1alpha (HIF-1alpha)-deficient tumors, which grow along preexisting brain capillaries without inducing neovessels.
|
15459006 |
2005 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
One family member, RGS5, has recently been identified as a key regulator of vascular remodeling and pericyte maturation in tumors.
|
19467451 |
2009 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
We found high-frequency expression of MAGE-A9 and NY-ESO-1 in 36% and 55% of samples, respectively, and overexpression of PRAME, RAGE-1, CA-IX, Cyclin D1, ADFP, C-MET, and RGS-5 in many of the tumor samples.
|
24777966 |
2013 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
RGS5 expression by the cancer vasculature triggered and retained by the proangiogenic microenvironment supports its exploitation as a novel biomarker and opens the path to explore new possibilities of therapeutic intervention aimed at targeting tumor blood vessels.
|
22130514 |
2012 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Immunohistochemical staining using serial sections for endothelial cell markers (CD31 and CD34) and smooth muscle cell markers (alpha-SMA and desmin), as well as fluorescence double staining, strongly suggested that tumour endothelial cells were the main location of RGS5 in RCC.
|
15095478 |
2004 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Twenty-six genes, including TFF3, DACH1, RGS5, and GHR, were shown to exhibit altered expression in tumors from patients with recurrence versus non-recurrent (fold change ≥1.5, p < 0.05), and the gene expression alterations were confirmed using qRT-PCR.
|
26585578 |
2015 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Our results indicated that RGS5 may be a potential target for cancer therapy.
|
25891540 |
2015 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
The regulator of G-protein signaling 5 (RGS5) has been reported to be highly expressed in some malignant tumors.
|
23868206 |
2013 |